English
简体中文
Total: £ 56.28
Published Date: 2025-11-12 | Pages: 146 | Tables: 154 | Medical Care
The global Skin Substitutes from Biological Sources market is projected to grow from US$ 1900 million in 2024 to US$ 4107 million by 2031, at a CAGR of 11.8% (2025-2031), driven by critical product segments and diverse end‑use applications.
Biological skin consists of the outer epidermis and/or dermis (the layer of skin between the epidermis and subcutaneous tissue) embedded in an acellular matrix (supporting structure) to form a biological skin substitute. Products are made from a variety of sources, including human tissue (from patients or others), non-human tissue (bovine, porcine, horse), synthetic materials (man-made), or a combination of these materials.
From a downstream perspective, Hospitals accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Skin Substitutes from Biological Sources leading manufacturers including Allergan (AbbVie), AlloSource, Organogenesis, BD, Smith & Nephew, Integra LifeSciences, Synthes (Johnson & Johnson), Axogen, Vericel Corporation, LifeNet Health, etc., dominate supply; the top five capture approximately % of global revenue, with Allergan (AbbVie) leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Skin Substitutes from Biological Sources market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Allergan (AbbVie)
AlloSource
Organogenesis
BD
Smith & Nephew
Integra LifeSciences
Synthes (Johnson & Johnson)
Axogen
Vericel Corporation
LifeNet Health
MTF Biologics
Arthrex
Wright Medical Group NV (Stryker)
Cook Biotech Incorporated
Aroa Biosurgery
Surgalign Holdings
Anika Therapeutics
Forticell Bioscience
MLM Biologics
Promethean LifeSciences
Segment by Type
Allogeneic Acellular Cells
Xenogeneic Cells
Allogeneic Cells
Autologous Cells
Segment by Application
Hospitals
Specialty Clinics
Wound Care Centers
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Skin Substitutes from Biological Sources study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Skin Substitutes from Biological Sources: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Skin Substitutes from Biological Sources Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Allogeneic Acellular Cells
1.2.3 Xenogeneic Cells
1.2.4 Allogeneic Cells
1.2.5 Autologous Cells
1.3 Market Segmentation by Application
1.3.1 Global Skin Substitutes from Biological Sources Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Wound Care Centers
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Skin Substitutes from Biological Sources Revenue Estimates and Forecasts 2020-2031
2.2 Global Skin Substitutes from Biological Sources Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Skin Substitutes from Biological Sources Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Skin Substitutes from Biological Sources Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Allogeneic Acellular Cells Market Size by Players
3.3.2 Xenogeneic Cells Market Size by Players
3.3.3 Allogeneic Cells Market Size by Players
3.3.4 Autologous Cells Market Size by Players
3.4 Global Skin Substitutes from Biological Sources Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Skin Substitutes from Biological Sources Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Skin Substitutes from Biological Sources Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Skin Substitutes from Biological Sources Market Size by Type (2020-2031)
6.4 North America Skin Substitutes from Biological Sources Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Skin Substitutes from Biological Sources Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Skin Substitutes from Biological Sources Market Size by Type (2020-2031)
7.4 Europe Skin Substitutes from Biological Sources Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Skin Substitutes from Biological Sources Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Skin Substitutes from Biological Sources Market Size by Type (2020-2031)
8.4 Asia-Pacific Skin Substitutes from Biological Sources Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Skin Substitutes from Biological Sources Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Skin Substitutes from Biological Sources Market Size by Type (2020-2031)
9.4 Central and South America Skin Substitutes from Biological Sources Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Skin Substitutes from Biological Sources Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Skin Substitutes from Biological Sources Market Size by Type (2020-2031)
10.4 Middle East and Africa Skin Substitutes from Biological Sources Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Skin Substitutes from Biological Sources Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Allergan (AbbVie)
11.1.1 Allergan (AbbVie) Corporation Information
11.1.2 Allergan (AbbVie) Business Overview
11.1.3 Allergan (AbbVie) Skin Substitutes from Biological Sources Product Features and Attributes
11.1.4 Allergan (AbbVie) Skin Substitutes from Biological Sources Revenue and Gross Margin (2020-2025)
11.1.5 Allergan (AbbVie) Skin Substitutes from Biological Sources Revenue by Product in 2024
11.1.6 Allergan (AbbVie) Skin Substitutes from Biological Sources Revenue by Application in 2024
11.1.7 Allergan (AbbVie) Skin Substitutes from Biological Sources Revenue by Geographic Area in 2024
11.1.8 Allergan (AbbVie) Skin Substitutes from Biological Sources SWOT Analysis
11.1.9 Allergan (AbbVie) Recent Developments
11.2 AlloSource
11.2.1 AlloSource Corporation Information
11.2.2 AlloSource Business Overview
11.2.3 AlloSource Skin Substitutes from Biological Sources Product Features and Attributes
11.2.4 AlloSource Skin Substitutes from Biological Sources Revenue and Gross Margin (2020-2025)
11.2.5 AlloSource Skin Substitutes from Biological Sources Revenue by Product in 2024
11.2.6 AlloSource Skin Substitutes from Biological Sources Revenue by Application in 2024
11.2.7 AlloSource Skin Substitutes from Biological Sources Revenue by Geographic Area in 2024
11.2.8 AlloSource Skin Substitutes from Biological Sources SWOT Analysis
11.2.9 AlloSource Recent Developments
11.3 Organogenesis
11.3.1 Organogenesis Corporation Information
11.3.2 Organogenesis Business Overview
11.3.3 Organogenesis Skin Substitutes from Biological Sources Product Features and Attributes
11.3.4 Organogenesis Skin Substitutes from Biological Sources Revenue and Gross Margin (2020-2025)
11.3.5 Organogenesis Skin Substitutes from Biological Sources Revenue by Product in 2024
11.3.6 Organogenesis Skin Substitutes from Biological Sources Revenue by Application in 2024
11.3.7 Organogenesis Skin Substitutes from Biological Sources Revenue by Geographic Area in 2024
11.3.8 Organogenesis Skin Substitutes from Biological Sources SWOT Analysis
11.3.9 Organogenesis Recent Developments
11.4 BD
11.4.1 BD Corporation Information
11.4.2 BD Business Overview
11.4.3 BD Skin Substitutes from Biological Sources Product Features and Attributes
11.4.4 BD Skin Substitutes from Biological Sources Revenue and Gross Margin (2020-2025)
11.4.5 BD Skin Substitutes from Biological Sources Revenue by Product in 2024
11.4.6 BD Skin Substitutes from Biological Sources Revenue by Application in 2024
11.4.7 BD Skin Substitutes from Biological Sources Revenue by Geographic Area in 2024
11.4.8 BD Skin Substitutes from Biological Sources SWOT Analysis
11.4.9 BD Recent Developments
11.5 Smith & Nephew
11.5.1 Smith & Nephew Corporation Information
11.5.2 Smith & Nephew Business Overview
11.5.3 Smith & Nephew Skin Substitutes from Biological Sources Product Features and Attributes
11.5.4 Smith & Nephew Skin Substitutes from Biological Sources Revenue and Gross Margin (2020-2025)
11.5.5 Smith & Nephew Skin Substitutes from Biological Sources Revenue by Product in 2024
11.5.6 Smith & Nephew Skin Substitutes from Biological Sources Revenue by Application in 2024
11.5.7 Smith & Nephew Skin Substitutes from Biological Sources Revenue by Geographic Area in 2024
11.5.8 Smith & Nephew Skin Substitutes from Biological Sources SWOT Analysis
11.5.9 Smith & Nephew Recent Developments
11.6 Integra LifeSciences
11.6.1 Integra LifeSciences Corporation Information
11.6.2 Integra LifeSciences Business Overview
11.6.3 Integra LifeSciences Skin Substitutes from Biological Sources Product Features and Attributes
11.6.4 Integra LifeSciences Skin Substitutes from Biological Sources Revenue and Gross Margin (2020-2025)
11.6.5 Integra LifeSciences Recent Developments
11.7 Synthes (Johnson & Johnson)
11.7.1 Synthes (Johnson & Johnson) Corporation Information
11.7.2 Synthes (Johnson & Johnson) Business Overview
11.7.3 Synthes (Johnson & Johnson) Skin Substitutes from Biological Sources Product Features and Attributes
11.7.4 Synthes (Johnson & Johnson) Skin Substitutes from Biological Sources Revenue and Gross Margin (2020-2025)
11.7.5 Synthes (Johnson & Johnson) Recent Developments
11.8 Axogen
11.8.1 Axogen Corporation Information
11.8.2 Axogen Business Overview
11.8.3 Axogen Skin Substitutes from Biological Sources Product Features and Attributes
11.8.4 Axogen Skin Substitutes from Biological Sources Revenue and Gross Margin (2020-2025)
11.8.5 Axogen Recent Developments
11.9 Vericel Corporation
11.9.1 Vericel Corporation Corporation Information
11.9.2 Vericel Corporation Business Overview
11.9.3 Vericel Corporation Skin Substitutes from Biological Sources Product Features and Attributes
11.9.4 Vericel Corporation Skin Substitutes from Biological Sources Revenue and Gross Margin (2020-2025)
11.9.5 Vericel Corporation Recent Developments
11.10 LifeNet Health
11.10.1 LifeNet Health Corporation Information
11.10.2 LifeNet Health Business Overview
11.10.3 LifeNet Health Skin Substitutes from Biological Sources Product Features and Attributes
11.10.4 LifeNet Health Skin Substitutes from Biological Sources Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 MTF Biologics
11.11.1 MTF Biologics Corporation Information
11.11.2 MTF Biologics Business Overview
11.11.3 MTF Biologics Skin Substitutes from Biological Sources Product Features and Attributes
11.11.4 MTF Biologics Skin Substitutes from Biological Sources Revenue and Gross Margin (2020-2025)
11.11.5 MTF Biologics Recent Developments
11.12 Arthrex
11.12.1 Arthrex Corporation Information
11.12.2 Arthrex Business Overview
11.12.3 Arthrex Skin Substitutes from Biological Sources Product Features and Attributes
11.12.4 Arthrex Skin Substitutes from Biological Sources Revenue and Gross Margin (2020-2025)
11.12.5 Arthrex Recent Developments
11.13 Wright Medical Group NV (Stryker)
11.13.1 Wright Medical Group NV (Stryker) Corporation Information
11.13.2 Wright Medical Group NV (Stryker) Business Overview
11.13.3 Wright Medical Group NV (Stryker) Skin Substitutes from Biological Sources Product Features and Attributes
11.13.4 Wright Medical Group NV (Stryker) Skin Substitutes from Biological Sources Revenue and Gross Margin (2020-2025)
11.13.5 Wright Medical Group NV (Stryker) Recent Developments
11.14 Cook Biotech Incorporated
11.14.1 Cook Biotech Incorporated Corporation Information
11.14.2 Cook Biotech Incorporated Business Overview
11.14.3 Cook Biotech Incorporated Skin Substitutes from Biological Sources Product Features and Attributes
11.14.4 Cook Biotech Incorporated Skin Substitutes from Biological Sources Revenue and Gross Margin (2020-2025)
11.14.5 Cook Biotech Incorporated Recent Developments
11.15 Aroa Biosurgery
11.15.1 Aroa Biosurgery Corporation Information
11.15.2 Aroa Biosurgery Business Overview
11.15.3 Aroa Biosurgery Skin Substitutes from Biological Sources Product Features and Attributes
11.15.4 Aroa Biosurgery Skin Substitutes from Biological Sources Revenue and Gross Margin (2020-2025)
11.15.5 Aroa Biosurgery Recent Developments
11.16 Surgalign Holdings
11.16.1 Surgalign Holdings Corporation Information
11.16.2 Surgalign Holdings Business Overview
11.16.3 Surgalign Holdings Skin Substitutes from Biological Sources Product Features and Attributes
11.16.4 Surgalign Holdings Skin Substitutes from Biological Sources Revenue and Gross Margin (2020-2025)
11.16.5 Surgalign Holdings Recent Developments
11.17 Anika Therapeutics
11.17.1 Anika Therapeutics Corporation Information
11.17.2 Anika Therapeutics Business Overview
11.17.3 Anika Therapeutics Skin Substitutes from Biological Sources Product Features and Attributes
11.17.4 Anika Therapeutics Skin Substitutes from Biological Sources Revenue and Gross Margin (2020-2025)
11.17.5 Anika Therapeutics Recent Developments
11.18 Forticell Bioscience
11.18.1 Forticell Bioscience Corporation Information
11.18.2 Forticell Bioscience Business Overview
11.18.3 Forticell Bioscience Skin Substitutes from Biological Sources Product Features and Attributes
11.18.4 Forticell Bioscience Skin Substitutes from Biological Sources Revenue and Gross Margin (2020-2025)
11.18.5 Forticell Bioscience Recent Developments
11.19 MLM Biologics
11.19.1 MLM Biologics Corporation Information
11.19.2 MLM Biologics Business Overview
11.19.3 MLM Biologics Skin Substitutes from Biological Sources Product Features and Attributes
11.19.4 MLM Biologics Skin Substitutes from Biological Sources Revenue and Gross Margin (2020-2025)
11.19.5 MLM Biologics Recent Developments
11.20 Promethean LifeSciences
11.20.1 Promethean LifeSciences Corporation Information
11.20.2 Promethean LifeSciences Business Overview
11.20.3 Promethean LifeSciences Skin Substitutes from Biological Sources Product Features and Attributes
11.20.4 Promethean LifeSciences Skin Substitutes from Biological Sources Revenue and Gross Margin (2020-2025)
11.20.5 Promethean LifeSciences Recent Developments
12 Skin Substitutes from Biological SourcesIndustry Chain Analysis
12.1 Skin Substitutes from Biological Sources Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Skin Substitutes from Biological Sources Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Skin Substitutes from Biological Sources Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Skin Substitutes from Biological Sources Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Skin Substitutes from Biological Sources Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Skin Substitutes from Biological Sources Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Skin Substitutes from Biological Sources Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Skin Substitutes from Biological Sources Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Skin Substitutes from Biological Sources Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Skin Substitutes from Biological Sources Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Skin Substitutes from Biological Sources by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Skin Substitutes from Biological Sources as of 2024)
Table 11. Global Skin Substitutes from Biological Sources Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Skin Substitutes from Biological Sources Companies Headquarters
Table 13. Global Skin Substitutes from Biological Sources Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Skin Substitutes from Biological Sources Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Skin Substitutes from Biological Sources Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Skin Substitutes from Biological Sources Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Skin Substitutes from Biological Sources Revenue by Application (2026-2031) & (US$ Million)
Table 21. Skin Substitutes from Biological Sources High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Skin Substitutes from Biological Sources Growth Accelerators and Market Barriers
Table 25. North America Skin Substitutes from Biological Sources Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Skin Substitutes from Biological Sources Growth Accelerators and Market Barriers
Table 27. Europe Skin Substitutes from Biological Sources Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Skin Substitutes from Biological Sources Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Skin Substitutes from Biological Sources Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Skin Substitutes from Biological Sources Investment Opportunities and Key Challenges
Table 31. Central and South America Skin Substitutes from Biological Sources Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Skin Substitutes from Biological Sources Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Skin Substitutes from Biological Sources Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Allergan (AbbVie) Corporation Information
Table 35. Allergan (AbbVie) Description and Major Businesses
Table 36. Allergan (AbbVie) Product Features and Attributes
Table 37. Allergan (AbbVie) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Allergan (AbbVie) Revenue Proportion by Product in 2024
Table 39. Allergan (AbbVie) Revenue Proportion by Application in 2024
Table 40. Allergan (AbbVie) Revenue Proportion by Geographic Area in 2024
Table 41. Allergan (AbbVie) Skin Substitutes from Biological Sources SWOT Analysis
Table 42. Allergan (AbbVie) Recent Developments
Table 43. AlloSource Corporation Information
Table 44. AlloSource Description and Major Businesses
Table 45. AlloSource Product Features and Attributes
Table 46. AlloSource Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. AlloSource Revenue Proportion by Product in 2024
Table 48. AlloSource Revenue Proportion by Application in 2024
Table 49. AlloSource Revenue Proportion by Geographic Area in 2024
Table 50. AlloSource Skin Substitutes from Biological Sources SWOT Analysis
Table 51. AlloSource Recent Developments
Table 52. Organogenesis Corporation Information
Table 53. Organogenesis Description and Major Businesses
Table 54. Organogenesis Product Features and Attributes
Table 55. Organogenesis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Organogenesis Revenue Proportion by Product in 2024
Table 57. Organogenesis Revenue Proportion by Application in 2024
Table 58. Organogenesis Revenue Proportion by Geographic Area in 2024
Table 59. Organogenesis Skin Substitutes from Biological Sources SWOT Analysis
Table 60. Organogenesis Recent Developments
Table 61. BD Corporation Information
Table 62. BD Description and Major Businesses
Table 63. BD Product Features and Attributes
Table 64. BD Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. BD Revenue Proportion by Product in 2024
Table 66. BD Revenue Proportion by Application in 2024
Table 67. BD Revenue Proportion by Geographic Area in 2024
Table 68. BD Skin Substitutes from Biological Sources SWOT Analysis
Table 69. BD Recent Developments
Table 70. Smith & Nephew Corporation Information
Table 71. Smith & Nephew Description and Major Businesses
Table 72. Smith & Nephew Product Features and Attributes
Table 73. Smith & Nephew Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Smith & Nephew Revenue Proportion by Product in 2024
Table 75. Smith & Nephew Revenue Proportion by Application in 2024
Table 76. Smith & Nephew Revenue Proportion by Geographic Area in 2024
Table 77. Smith & Nephew Skin Substitutes from Biological Sources SWOT Analysis
Table 78. Smith & Nephew Recent Developments
Table 79. Integra LifeSciences Corporation Information
Table 80. Integra LifeSciences Description and Major Businesses
Table 81. Integra LifeSciences Product Features and Attributes
Table 82. Integra LifeSciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Integra LifeSciences Recent Developments
Table 84. Synthes (Johnson & Johnson) Corporation Information
Table 85. Synthes (Johnson & Johnson) Description and Major Businesses
Table 86. Synthes (Johnson & Johnson) Product Features and Attributes
Table 87. Synthes (Johnson & Johnson) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Synthes (Johnson & Johnson) Recent Developments
Table 89. Axogen Corporation Information
Table 90. Axogen Description and Major Businesses
Table 91. Axogen Product Features and Attributes
Table 92. Axogen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Axogen Recent Developments
Table 94. Vericel Corporation Corporation Information
Table 95. Vericel Corporation Description and Major Businesses
Table 96. Vericel Corporation Product Features and Attributes
Table 97. Vericel Corporation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Vericel Corporation Recent Developments
Table 99. LifeNet Health Corporation Information
Table 100. LifeNet Health Description and Major Businesses
Table 101. LifeNet Health Product Features and Attributes
Table 102. LifeNet Health Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. LifeNet Health Recent Developments
Table 104. MTF Biologics Corporation Information
Table 105. MTF Biologics Description and Major Businesses
Table 106. MTF Biologics Product Features and Attributes
Table 107. MTF Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. MTF Biologics Recent Developments
Table 109. Arthrex Corporation Information
Table 110. Arthrex Description and Major Businesses
Table 111. Arthrex Product Features and Attributes
Table 112. Arthrex Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Arthrex Recent Developments
Table 114. Wright Medical Group NV (Stryker) Corporation Information
Table 115. Wright Medical Group NV (Stryker) Description and Major Businesses
Table 116. Wright Medical Group NV (Stryker) Product Features and Attributes
Table 117. Wright Medical Group NV (Stryker) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Wright Medical Group NV (Stryker) Recent Developments
Table 119. Cook Biotech Incorporated Corporation Information
Table 120. Cook Biotech Incorporated Description and Major Businesses
Table 121. Cook Biotech Incorporated Product Features and Attributes
Table 122. Cook Biotech Incorporated Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Cook Biotech Incorporated Recent Developments
Table 124. Aroa Biosurgery Corporation Information
Table 125. Aroa Biosurgery Description and Major Businesses
Table 126. Aroa Biosurgery Product Features and Attributes
Table 127. Aroa Biosurgery Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. Aroa Biosurgery Recent Developments
Table 129. Surgalign Holdings Corporation Information
Table 130. Surgalign Holdings Description and Major Businesses
Table 131. Surgalign Holdings Product Features and Attributes
Table 132. Surgalign Holdings Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. Surgalign Holdings Recent Developments
Table 134. Anika Therapeutics Corporation Information
Table 135. Anika Therapeutics Description and Major Businesses
Table 136. Anika Therapeutics Product Features and Attributes
Table 137. Anika Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. Anika Therapeutics Recent Developments
Table 139. Forticell Bioscience Corporation Information
Table 140. Forticell Bioscience Description and Major Businesses
Table 141. Forticell Bioscience Product Features and Attributes
Table 142. Forticell Bioscience Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. Forticell Bioscience Recent Developments
Table 144. MLM Biologics Corporation Information
Table 145. MLM Biologics Description and Major Businesses
Table 146. MLM Biologics Product Features and Attributes
Table 147. MLM Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 148. MLM Biologics Recent Developments
Table 149. Promethean LifeSciences Corporation Information
Table 150. Promethean LifeSciences Description and Major Businesses
Table 151. Promethean LifeSciences Product Features and Attributes
Table 152. Promethean LifeSciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 153. Promethean LifeSciences Recent Developments
Table 154. Raw Materials Key Suppliers
Table 155. Distributors List
Table 156. Market Trends and Market Evolution
Table 157. Market Drivers and Opportunities
Table 158. Market Challenges, Risks, and Restraints
Table 159. Research Programs/Design for This Report
Table 160. Key Data Information from Secondary Sources
Table 161. Key Data Information from Primary Sources
List of Figures
Figure 1. Skin Substitutes from Biological Sources Product Picture
Figure 2. Global Skin Substitutes from Biological Sources Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Allogeneic Acellular Cells Product Picture
Figure 4. Xenogeneic Cells Product Picture
Figure 5. Allogeneic Cells Product Picture
Figure 6. Autologous Cells Product Picture
Figure 7. Global Skin Substitutes from Biological Sources Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Hospitals
Figure 9. Specialty Clinics
Figure 10. Wound Care Centers
Figure 11. Skin Substitutes from Biological Sources Report Years Considered
Figure 12. Global Skin Substitutes from Biological Sources Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Skin Substitutes from Biological Sources Revenue (2020-2031) & (US$ Million)
Figure 14. Global Skin Substitutes from Biological Sources Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Skin Substitutes from Biological Sources Revenue Market Share by Region (2020-2031)
Figure 16. Global Skin Substitutes from Biological Sources Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. Allogeneic Acellular Cells Revenue Market Share by Player in 2024
Figure 19. Xenogeneic Cells Revenue Market Share by Player in 2024
Figure 20. Allogeneic Cells Revenue Market Share by Player in 2024
Figure 21. Autologous Cells Revenue Market Share by Player in 2024
Figure 22. Global Skin Substitutes from Biological Sources Revenue Market Share by Type (2020-2031)
Figure 23. Global Skin Substitutes from Biological Sources Revenue Market Share by Application (2020-2031)
Figure 24. North America Skin Substitutes from Biological Sources Revenue YoY (2020-2031) & (US$ Million)
Figure 25. North America Top 5 Players Skin Substitutes from Biological Sources Revenue (US$ Million) in 2024
Figure 26. North America Skin Substitutes from Biological Sources Revenue (US$ Million) by Type (2020 - 2031)
Figure 27. North America Skin Substitutes from Biological Sources Revenue (US$ Million) by Application (2020-2031)
Figure 28. US Skin Substitutes from Biological Sources Revenue (2020-2031) & (US$ Million)
Figure 29. Canada Skin Substitutes from Biological Sources Revenue (2020-2031) & (US$ Million)
Figure 30. Mexico Skin Substitutes from Biological Sources Revenue (2020-2031) & (US$ Million)
Figure 31. Europe Skin Substitutes from Biological Sources Revenue YoY (2020-2031) & (US$ Million)
Figure 32. Europe Top 5 Players Skin Substitutes from Biological Sources Revenue (US$ Million) in 2024
Figure 33. Europe Skin Substitutes from Biological Sources Revenue (US$ Million) by Type (2020-2031)
Figure 34. Europe Skin Substitutes from Biological Sources Revenue (US$ Million) by Application (2020-2031)
Figure 35. Germany Skin Substitutes from Biological Sources Revenue (2020-2031) & (US$ Million)
Figure 36. France Skin Substitutes from Biological Sources Revenue (2020-2031) & (US$ Million)
Figure 37. U.K. Skin Substitutes from Biological Sources Revenue (2020-2031) & (US$ Million)
Figure 38. Italy Skin Substitutes from Biological Sources Revenue (2020-2031) & (US$ Million)
Figure 39. Russia Skin Substitutes from Biological Sources Revenue (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Skin Substitutes from Biological Sources Revenue YoY (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Top 8 Players Skin Substitutes from Biological Sources Revenue (US$ Million) in 2024
Figure 42. Asia-Pacific Skin Substitutes from Biological Sources Revenue (US$ Million) by Type (2020-2031)
Figure 43. Asia-Pacific Skin Substitutes from Biological Sources Revenue (US$ Million) by Application (2020-2031)
Figure 44. Indonesia Skin Substitutes from Biological Sources Revenue (2020-2031) & (US$ Million)
Figure 45. Japan Skin Substitutes from Biological Sources Revenue (2020-2031) & (US$ Million)
Figure 46. South Korea Skin Substitutes from Biological Sources Revenue (2020-2031) & (US$ Million)
Figure 47. Australia Skin Substitutes from Biological Sources Revenue (2020-2031) & (US$ Million)
Figure 48. India Skin Substitutes from Biological Sources Revenue (2020-2031) & (US$ Million)
Figure 49. Indonesia Skin Substitutes from Biological Sources Revenue (2020-2031) & (US$ Million)
Figure 50. Vietnam Skin Substitutes from Biological Sources Revenue (2020-2031) & (US$ Million)
Figure 51. Malaysia Skin Substitutes from Biological Sources Revenue (2020-2031) & (US$ Million)
Figure 52. Philippines Skin Substitutes from Biological Sources Revenue (2020-2031) & (US$ Million)
Figure 53. Singapore Skin Substitutes from Biological Sources Revenue (2020-2031) & (US$ Million)
Figure 54. Central and South America Skin Substitutes from Biological Sources Revenue YoY (2020-2031) & (US$ Million)
Figure 55. Central and South America Top 5 Players Skin Substitutes from Biological Sources Revenue (US$ Million) in 2024
Figure 56. Central and South America Skin Substitutes from Biological Sources Revenue (US$ Million) by Type (2020-2031)
Figure 57. Central and South America Skin Substitutes from Biological Sources Revenue (US$ Million) by Application (2020-2031)
Figure 58. Brazil Skin Substitutes from Biological Sources Revenue (2020-2025) & (US$ Million)
Figure 59. Argentina Skin Substitutes from Biological Sources Revenue (2020-2025) & (US$ Million)
Figure 60. Middle East and Africa Skin Substitutes from Biological Sources Revenue YoY (2020-2031) & (US$ Million)
Figure 61. Middle East and Africa Top 5 Players Skin Substitutes from Biological Sources Revenue (US$ Million) in 2024
Figure 62. South America Skin Substitutes from Biological Sources Revenue (US$ Million) by Type (2020-2031)
Figure 63. Middle East and Africa Skin Substitutes from Biological Sources Revenue (US$ Million) by Application (2020-2031)
Figure 64. GCC Countries Skin Substitutes from Biological Sources Revenue (2020-2025) & (US$ Million)
Figure 65. Israel Skin Substitutes from Biological Sources Revenue (2020-2025) & (US$ Million)
Figure 66. Egypt Skin Substitutes from Biological Sources Revenue (2020-2025) & (US$ Million)
Figure 67. South Africa Skin Substitutes from Biological Sources Revenue (2020-2025) & (US$ Million)
Figure 68. Skin Substitutes from Biological Sources Industry Chain Mapping
Figure 69. Channels of Distribution (Direct Vs Distribution)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
